

**CCL17 Antibody**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP21571a**

**Specification**

---

**CCL17 Antibody - Product Information**

Application	<b>WB, FC,E</b>
Primary Accession	<a href="#">O92583</a>
Reactivity	<b>Human</b>
Host	<b>Rabbit</b>
Clonality	<b>polyclonal</b>
Isotype	<b>Rabbit IgG</b>
Calculated MW	<b>10507</b>

**CCL17 Antibody - Additional Information**

**Gene ID** 6361

**Other Names**

C-C motif chemokine 17, CC chemokine TARC, Small-inducible cytokine A17, Thymus and activation-regulated chemokine, CCL17, SCYA17, TARC

**Target/Specificity**

This CCL17 antibody is generated from a rabbit immunized with a recombinant protein of human CCL17.

**Dilution**

WB~~1:2000

FC~~1:25

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

CCL17 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

**CCL17 Antibody - Protein Information**

**Name** CCL17

**Synonyms** SCYA17, TARC

**Function** Chemokine, which displays chemotactic activity for T lymphocytes, preferentially Th2

cells, but not monocytes or granulocytes. Therefore plays an important role in a wide range of inflammatory and immunological processes (PubMed:[8702936](#), PubMed:[9169480](#)). Acts by binding to CCR4 at T-cell surface (PubMed:[10540332](#), PubMed:[9169480](#)). Mediates GM-CSF/CSF2-driven pain and inflammation (PubMed:[27525438](#)). In the brain, required to maintain the typical, highly branched morphology of hippocampal microglia under homeostatic conditions. May be important for the appropriate adaptation of microglial morphology and synaptic plasticity to acute lipopolysaccharide (LPS)-induced neuroinflammation (By similarity). Plays a role in wound healing, mainly by inducing fibroblast migration into the wound (By similarity).

#### Cellular Location

Secreted

#### Tissue Location


Constitutively expressed in thymus. Detected at lower levels in the lung, colon and small intestine (PubMed:[8702936](#)) Expressed in stimulated peripheral blood mononuclear cells, but not in resting cells (PubMed:[8702936](#)).

### CCL17 Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### CCL17 Antibody - Images



All lanes : Anti-CCL17 Antibody at 1:2000 dilution Lane 1: human spleen lysates Lane 2: human skeletal muscle lysates Lane 3: human lung lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 11 kDa Blocking/Dilution buffer: 5% NFDN/TBST.



Overlay histogram showing Jurkat cells stained with AP21571a (green line). The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min. The cells were then incubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (AP21571a, 1:25 dilution) for 60 min at 37°C. The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OH191631) at 1/200 dilution for 40 min at 37°C. Isotype control antibody (blue line) was rabbit IgG (1µg/1x10<sup>6</sup> cells) used under the same conditions. Acquisition of >10, 000 events was performed.

### **CCL17 Antibody - Background**

Chemotactic factor for T-lymphocytes but not monocytes or granulocytes. May play a role in T-cell development in thymus and in trafficking and activation of mature T-cells. Binds to CCR4.

### **CCL17 Antibody - References**

- Imai T., et al. J. Biol. Chem. 271:21514-21521(1996).
- Livingston R.J., et al. Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
- Loftus B.J., et al. Genomics 60:295-308(1999).
- Mural R.J., et al. Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
- Bernardini G., et al. Eur. J. Immunol. 28:582-588(1998).

### **CCL17 Antibody - Citations**

- [Transcriptome analysis reveals GPNMB as a potential therapeutic target for gastric cancer.](#)